Elsevier eBooks, Год журнала: 2024, Номер unknown, С. 457 - 463
Опубликована: Янв. 1, 2024
Язык: Английский
World Journal of Gastroenterology, Год журнала: 2023, Номер 29(5), С. 815 - 824
Опубликована: Фев. 2, 2023
Coronavirus disease 2019 (COVID-19) is primarily a respiratory with multi-organ involvement, including impaired liver function. It has been noticed that significant proportion of COVID-19 patients have dysfunction, especially those more severe course. The coronavirus causes direct damage to the using angiotensin-converting enzyme 2, cell-surface receptor for cellular entry, expressed in liver. According previous research, abnormalities were observed considerable patients, and elevated transaminases found about 20% these alkaline phosphatase 6.1%, gamma-glutamyl transferase 21.1%. might trigger deterioration function pre-existing chronic diseases (CLDs) also without disorders. majority who develop injury are men, elderly, higher body mass index. Compared general population, associated morbidity mortality (cirrhosis transplantation recipients). However, some studies indicate CLDs lesser role determining patient progression towards severity.
Язык: Английский
Процитировано
19
World Journal of Gastroenterology, Год журнала: 2023, Номер 29(2), С. 367 - 377
Опубликована: Янв. 5, 2023
The pandemics of coronavirus disease 2019 (COVID-19) and non-alcoholic fatty liver (NAFLD) coexist. Elevated function tests are frequent in COVID-19 may influence damage NAFLD, while preexisting from NAFLD the course COVID-19. However, prognostic relevance this interaction, though, is unclear. Obesity a risk factor for presence as well severe Cohort studies reveal conflicting results regarding on illness severity. Striking molecular similarities cytokine pathways both diseases, including postacute sequelae COVID-19, suggest common chronic low-activity inflammation. This review will summarize existing data interaction diseases discuss possible mechanisms one other.
Язык: Английский
Процитировано
14
Viruses, Год журнала: 2023, Номер 15(5), С. 1072 - 1072
Опубликована: Апрель 27, 2023
The global population is currently experiencing the impact of SARS-CoV-2 coronavirus, which has caused Coronavirus Disease 2019 (COVID-19) pandemic. With our profound comprehension COVID-19, encompassing involvement sequence respiratory tract, gastrointestinal system, and cardiovascular apparatus, multiorgan symptoms this infectious disease have been discerned. Metabolic-associated fatty liver (MAFLD), formerly known as non-alcoholic (NAFLD), a pervasive public health concern intricately linked with metabolic dysregulation estimated to afflict one-fourth adult population. burgeoning focus on association between COVID-19 MAFLD justified by potential role latter risk factor for both infection subsequent emergence severe symptoms. Investigations suggested that changes in innate adaptive immune responses among patients may play determining severity COVID-19. remarkable similarities observed cytokine pathways implicated diseases imply existence shared mechanisms governing chronic inflammatory characterizing these conditions. effect illness remains uncertain, indicated conflicting results cohort investigations.
Язык: Английский
Процитировано
14
Narra J, Год журнала: 2023, Номер 3(1), С. e102 - e102
Опубликована: Апрель 28, 2023
It is important to identify risk factors for poor outcomes of coronavirus disease 2019 (COVID-19) patients. Currently, the correlation between non-alcoholic fatty liver (NAFLD) and COVID-19 has not been established. This study was conducted determine association NAFLD in-hospital The systematic searches were by using PubMed Europe PMC databases particular keywords used as December 10, 2020. Further up 2022. All articles that include data about collected. Statistical analysis performed Review Manager 5.4 Comprehensive Meta-Analysis version 3 software. A total 7,210 patients from 18 studies included in final analysis. Meta-analysis revealed increased developing outcome (pooled both severe death) (RR 1.42; 95%CI: 1.17–1.73, p<0.001, I2=84%, random-effect modeling). Subgroup however found having only chance getting 1.67; 1.32–2.13, I2=86%, modeling) mortality 1.00; 0.68–1.47, p=0.98, I2=80%, Meta-regression suggested age (p=0.001) diabetes (p=0.029) significantly influenced relationship mortality). weaker with median ≥45 years old 1.29) when compared <45 2.96). In addition, prevalence ≥25% had a <25% 1.85). conclusion, therefore it should be evaluated closely reduce COVID-19.
Язык: Английский
Процитировано
13
Life, Год журнала: 2024, Номер 14(1), С. 93 - 93
Опубликована: Янв. 7, 2024
The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) continues to rise, making it one the most prevalent chronic disorders. MASLD encompasses a range pathologies, from simple steatosis steatohepatitis (MASH) with inflammation, hepatocyte damage, and fibrosis. Interestingly, exhibits close intercommunication fatty tissue. In fact, adipose tissue could contribute etiology advancement MASLD, acting as an endocrine organ that releases several hormones cytokines, adipokines assuming pivotal role. levels in blood are altered people recent research has shed light on crucial role played by regulating energy expenditure, fibrosis MASLD. However, is multifaceted condition affects various aspects health beyond function, including its impact hemostasis. alterations coagulation mechanisms endothelial platelet functions may play increased vulnerability severity Therefore, more attention being given imbalanced causative agents causing disturbances hemostasis Metabolic inflammation hepatic injury fundamental components interrelation between these biological pathway delineated reciprocal influences, well induction alterations. Adipokines have potential serve shared elements within this complex interrelationship. objective review thoroughly examine existing scientific knowledge impairment connection adipokines, aim enhancing our comprehension disease.
Язык: Английский
Процитировано
5
Journal of Clinical Medicine, Год журнала: 2024, Номер 13(3), С. 798 - 798
Опубликована: Янв. 30, 2024
Background: While it has been shown that steatotic liver disease (SLD) is associated with systemic changes in immune response, the impact of SLD on sepsis outcomes not yet established. The aim this study was to investigate association between and severity outcomes. Methods: A prospective observational included consecutively hospitalized adult patients community-acquired during a 16-month period. Results: Of 378 (49.5% male, median age 69, IQR 57–78 years), 174 (46%) were diagnosed SLD. Patients older more frequently fulfilled criteria for metabolic syndrome. There no differences source etiology groups. exhibited higher incidence acute kidney injury (29.3% vs. 17.6%), need renal replacement therapy (16.1% 8.8%), frequent use invasive mechanical ventilation 18.1%). In-hospital mortality significantly group (18.39% 9.8%). multivariable analysis indicated (HR 2.82, 95% CI 1.40–5.71) irrespective other elements within Conclusions: might be in-hospital mortality, development respiratory insufficiency requiring critical care support.
Язык: Английский
Процитировано
5
International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(5), С. 2226 - 2226
Опубликована: Март 1, 2025
Metabolic dysfunction-associated steatotic liver disease (MASLD) has recently been linked with sepsis outcomes. However, the immune mechanisms by which MASLD aggravates severity are unknown. This prospective cohort study aimed to analyze serum cytokine and chemokine kinetics in patients community-acquired sepsis. Out of 124 patients, 68 (55%) were diagnosed MASLD. There no differences age, sex, comorbidities, baseline severity, or etiology between groups. Serum concentrations 27 cytokines chemokines on admission day 5 hospitalization analyzed using a multiplex bead-based assay. Patients had significantly higher IL17A, IL-23, IL-33, CXCL10 TGF-β1. Different observed; decrease IL-10, TGF-β1, an increase CXCL5 CXCL1 5. In non-MASLD group, there was IFN-γ, IL-6, IL-23 CCL20, CCL11 CXCL5. While TGF-β1 increased non-MASLD, MASLD, it decreased Kinetics TGF- β1 associated mortality conclusion, is distinct profiles during
Язык: Английский
Процитировано
0
International Immunopharmacology, Год журнала: 2023, Номер 121, С. 110439 - 110439
Опубликована: Июнь 8, 2023
COVID-19-infected individuals and those who recovered from the infection have been demonstrated to elevated liver enzymes or abnormal biochemistries, particularly with preexisting diseases, metabolic disorders, viral hepatitis, other hepatic comorbidities. However, possible crosstalk intricate interplay between COVID-19 disease severity are still elusive, available data murky confined. Similarly, syndemic of blood-borne infectious chemical-induced injuries, chronic diseases continued take lives while showing signs worsening due crisis. Moreover, pandemic is not over yet transitioning becoming an epidemic in recent years; hence, monitoring function tests (LFTs) assessing consequences patients without illnesses would be paramount interest. This pragmatic review explores correlations based on biochemistries mechanisms all ages emergence post-pandemic period. The also alludes clinical perspectives such interactions curb overlapping people living long COVID-19.
Язык: Английский
Процитировано
10
Life, Год журнала: 2022, Номер 12(6), С. 795 - 795
Опубликована: Май 26, 2022
Non-alcoholic fatty liver disease (NAFLD) is identified as a risk factor for developing severe COVID-19. While NAFLD associated with chronic low-grade inflammation, mechanisms leading to immune system hyperactivation remain unclear. The aim of this prospective observational study analyze cytokine profiles in patients COVID-19 and NAFLD. A total 94 were included. Upon admission, clinical laboratory data collected, ultrasound was performed determine the presence steatosis, subsequently, 51 diagnosed according current guidelines. There no differences age, sex, comorbidities, baseline severity between groups. Serum concentrations analyzed using multiplex bead-based assay by flow cytometry. group had higher C-reactive protein, procalcitonin, alanine aminotransferase, lactate dehydrogenase, fibrinogen. Interleukins-6, -8, -10 CXCL10 significantly higher, while IFN-γ lower patients. Patients who progressed critical illness IL-6, -10, IFN-β, IL-8 IL-10 appear be effective prognostic biomarkers time recovery. In conclusion, distinct COVID-19, possibly adverse outcomes.
Язык: Английский
Процитировано
15
Life, Год журнала: 2022, Номер 12(12), С. 2052 - 2052
Опубликована: Дек. 7, 2022
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic disease, affecting one third of Western population. The hallmark excessive storage fat in liver. Most commonly, it caused by metabolic syndrome (or its components). Even though development NAFLD has multiple effects on human organism resulting systemic low-grade inflammation, this review focused as a risk factor for onset, progression, and outcomes infectious diseases. correlation between infections still unclear. Multiple factors (obesity, altered immune system function, insulin resistance, intestinal microbiota, etc.) have been proposed to play role progression people with NAFLD, although exact mechanism interplay mentioned mostly hypothesized. In article we only selection well-researched topics diseases (bacterial pneumonia, COVID, H. pylori, urinary tract infections, C. difficile, bacteremia, hepatitis B, C, HIV, periodontitis).
Язык: Английский
Процитировано
15